An Attractive Opportunity for Rare Disease and Healthcare Companies



The MENA region is very diverse, but one thing the countries in this region have in common is that their economies show sustainable emerging markets-type growth.

This growth and contributing socio-economic factors have had a significant impact on the healthcare sector, with governments “investing in healthcare infrastructures, in access to medicine and reimbursement schemes. Moreover, there is a clear trend towards privatizing medical insurance.”

The whitepaper looks at several key topics, including:

With an estimated 2.8 million patients suffering from a rare disease in the Middle East region, this truly is an interesting and unique frontier in the rare disease and orphan drug space.

Get you free copy of the White Paper Now!